Pacific Biosciences of California, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Pacific Biosciences of California, Inc. (PACB) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-06
- Pacific Biosciences of California, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $0.00.
- Pacific Biosciences of California, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Pacific Biosciences of California, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $25.00K.
- Pacific Biosciences of California, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- Pacific Biosciences of California, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $29.60M.
- Pacific Biosciences of California, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $2.58M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $25.00K derived: sum of 3 quarters · filed 2026-08-06 | $25.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-08 | $25.00K derived: sum of 2 quarters · filed 2026-05-08 | $25.00K derived: sum of 3 quarters · filed 2026-05-08 | $25.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $25.00K derived: sum of 2 quarters · filed 2026-02-25 | $25.00K derived: sum of 3 quarters · filed 2026-08-06 | $29.60M 10-K · filed 2026-02-25 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $29.57M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $29.57M 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $29.57M 10-Q · filed 2026-05-08 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 | |||
| 2021-12-31 | $2.58M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |